Last reviewed · How we verify

NCT04713410

Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome

Status unknown NA Last updated 11 May 2021
What this trial tests

NA trial testing Prednisolone in Steroid-Sensitive Nephrotic Syndrome in 68 participants. Status unknown.

Timeline
22 December 2020
Primary endpoint
4 September 2022
4 September 2023

Quick facts

Lead sponsorShaheed Zulfiqar Ali Bhutto Medical University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment68
Start date22 December 2020
Primary completion4 September 2022
Estimated completion4 September 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Shaheed Zulfiqar Ali Bhutto Medical University

Who can join

Adults 1 to 8, any sex, with Steroid-Sensitive Nephrotic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time will be divided into two groups. One group will be given steroids for 12 weeks and other group will receive steroid for 20 weeks. During the 1 years after completion of steroid course patients will be monitor for the episodes of relapse in both group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Prednisolone

Trials testing the same drug.

Other recruiting trials for Steroid-Sensitive Nephrotic Syndrome

Currently open trials in the same condition.

Other Shaheed Zulfiqar Ali Bhutto Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04713410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing